glucagon inhibitory peptide GIP and glucagon‐like peptide‐1 (GLP‐1 - Gastricinhibitory peptidefunction GLP-1 (glucagon-like peptide-1 Glucagon Inhibitory Peptide: Unraveling the Role of GIP in Metabolic Health

Gastricinhibitory peptidemedication The intricate world of metabolic regulation involves a complex interplay of hormones, each playing a crucial role in maintaining bodily functionsUnderstanding how glucagon-like peptide-1 (GLP1) and .... Among these, glucagon inhibitory peptide (GIP), also known as gastric inhibitory polypeptide or glucose-dependent insulinotropic peptide, stands out as a key player. This peptide hormone, secreted from the K cells in the intestinal epithelium, primarily in the proximal duodenum, is a vital component of the incretin system. The incretin effect, a phenomenon where oral glucose intake stimulates a greater insulin response than intravenous glucose administration, is largely attributed to the actions of GIP and its counterpart, glucagon-like peptide-1 (GLP-1).

GIP and GLP-1: The Incretin Duo

GIP, along with GLP-1, belongs to a class of hormones referred to as incretins. These peptides are released from the intestine in response to the ingestion of glucose or nutrients. Their primary function is to stimulate insulin release from pancreatic β cells in a glucose-dependent manner, thereby helping to regulate blood sugar levels after a meal. Research indicates that GIP is one of the principal incretin hormones, and together with GLP-1, accounts for a significant portion of the incretin effectGastric inhibitory polypeptide – Knowledge and References. While both hormones share the common goal of enhancing insulin secretion, they also possess distinct characteristics and roles in metabolic control.

The Multifaceted Actions of GIP

The primary and most well-documented action of GIP is its ability to stimulate insulin secretion. This effect is most pronounced when blood glucose levels are elevated, underscoring its role in postprandial glucose homeostasis.Glucagon-like peptide-1 (GLP-1) is a 30- or 31-amino-acid-long peptide hormone deriving from tissue-specific posttranslational processing of the proglucagon ... However, GIP's influence extends beyond insulin. Studies suggest that GIP can also stimulate glucagon secretion, although this effect is dependent on glucose concentrations. Specifically, GIP stimulates glucagon secretion at lower glucose levels (below 5.5 mmol/l), while at higher concentrations, the insulin-stimulating effect dominates. Conversely, GIP also plays a role in inhibiting glucagon secretion from pancreatic α cells, thereby reducing hepatic glucose production. This dual action highlights the nuanced regulatory capabilities of this hormone.作者：Y Seino·2010·被引用次数：908—GIP and glucagon‐like peptide‐1 (GLP‐1) are the two primary incretin hormones secreted from the intestine on ingestion of glucose or nutrients to stimulate ...

Furthermore, GIP has been implicated in influencing other aspects of metabolism. It can affect fat metabolism by promoting glucose uptake into adipocytes and stimulating triglyceride synthesisUnderstanding how glucagon-like peptide-1 (GLP1) and .... Emerging research also points towards GIP's involvement in appetite regulation and satiety, though its role in these areas is still being comprehensively investigated. The interaction between GIP and GLP-1 is particularly noteworthy, with dual agonists targeting both GIP and GLP-1 receptors showing promise as future therapeutic strategies for metabolic diseases.What are GLP-1 and GIP and How Do They Function?

GIP vs. GLP-1: Similarities and Differences

While both GIP and GLP-1 are incretin hormones secreted from the intestine and stimulate insulin release, they originate from different precursor molecules and have distinct physiological effects. GLP-1 is derived from the proglucagon gene, while GIP is encoded by a separate gene. Both hormones are rapidly degraded in the circulation by enzymes like dipeptidyl peptidase-4 (DPP-4), which limits their duration of action.Its main action is toencourage the release of insulin into the bloodstreamto control blood sugar levels. Glucagon-like peptide 1 Gonadotrophin-releasing ...

The therapeutic implications of understanding these peptides are significant.作者：R MENTLEIN·1993·被引用次数：1569—Peptides of the glucagon/vasoactive-intestinal-peptide (VIP) peptide familyshare a considerable sequence similarity at their N-terminus. Medications that mimic the action of GLP-1, often referred to as GLP-1 (glucagon-like peptide-1) mimics, have revolutionized the treatment of type 2 diabetes and obesityRipples of Discovery Created a New Wave of Weight-loss .... These drugs, such as semaglutide (Ozempic), work by binding to GLP-1 receptors, enhancing insulin secretion, suppressing glucagon release, slowing gastric emptying, and promoting satiety. The development of dual-acting agents that target both GLP-1 and GIP receptors, such as tirzepatide, represents a significant advancement, offering even greater efficacy in weight loss and glycemic control. For instance, CT-388 is a dual-acting treatment targeting GLP-1 (glucagon-like peptide-1) and GIP (gastric inhibitory peptide)作者：MSS Hansen·2018·被引用次数：39—The incretin hormones gastricinhibitory polypeptide(GIP) andglucagon-like peptide-1 (GLP-1) are secreted from the intestine in response to ....

Research and Therapeutic Potential

The scientific community continues to explore the full spectrum of GIP's functions and its potential as a therapeutic target. Research into gastric inhibitory polypeptide function is shedding light on its role in various physiological processes. Understanding the intricate signaling pathways involving GIP and its receptor (GIPR) is crucial for developing novel therapeutic interventions. For example, studies have investigated the structural insights into multiplexed pharmacological actions, such as cryo-electron microscopy structures of tirzepatide-bound GIPR and GLP-1RGIP, along with glucagon-like peptide-1 (GLP-1), belongs to a class of molecules referred to as incretins, which stimulate insulin release on oral food intake..

While the focus has often been on GLP-1, the importance of GIP is increasingly recognized. GIP and GLP-1 are incretin hormones that regulate glucose homeostasis through complementary mechanisms. The ability of GIP to encourage the release of insulin into the bloodstream to control blood sugar levels is a fundamental aspect of its physiological role. Furthermore, the concept of GIP and glucagon-like peptide-1 (GLP-1) working in tandem is central to the development of next-generation metabolic therapiesGlucagon-like peptide-1 and gastric inhibitory polypeptide.

In conclusion, glucagon inhibitory peptide (GIP) is a critical incretin hormone with significant roles in glucose homeostasis, insulin secretion, and potentially appetite regulation. Its close relationship with GLP-1 has paved the way for innovative therapeutic strategies, particularly in the management of type 2 diabetes and obesityGastric inhibitory peptide (GIP), pancreatic glucagon and .... As research progresses, a deeper understanding of these powerful hormones and their interactions will undoubtedly lead to further advancements in metabolic health.作者：MM Wolfe·2025·被引用次数：17—GIP is a 42-amino acid hormonethat is synthesized and released from upper intestinal enteroendocrine K cells in response to the ingestion of glucose or fat.